Digestive Manifestations in Patients Hospitalized With Coronavirus Disease 2019.
COVID-19
Digestive Manifestations
Gastrointestinal Symptoms
Hepatic Manifestations
SARS-CoV-2
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
10
09
2020
revised:
21
09
2020
accepted:
22
09
2020
pubmed:
4
10
2020
medline:
4
8
2021
entrez:
3
10
2020
Statut:
ppublish
Résumé
The prevalence and significance of digestive manifestations in coronavirus disease 2019 (COVID-19) remain uncertain. We aimed to assess the prevalence, spectrum, severity, and significance of digestive manifestations in patients hospitalized with COVID-19. Consecutive patients hospitalized with COVID-19 were identified across a geographically diverse alliance of medical centers in North America. Data pertaining to baseline characteristics, symptomatology, laboratory assessment, imaging, and endoscopic findings from the time of symptom onset until discharge or death were abstracted manually from electronic health records to characterize the prevalence, spectrum, and severity of digestive manifestations. Regression analyses were performed to evaluate the association between digestive manifestations and severe outcomes related to COVID-19. A total of 1992 patients across 36 centers met eligibility criteria and were included. Overall, 53% of patients experienced at least 1 gastrointestinal symptom at any time during their illness, most commonly diarrhea (34%), nausea (27%), vomiting (16%), and abdominal pain (11%). In 74% of cases, gastrointestinal symptoms were judged to be mild. In total, 35% of patients developed an abnormal alanine aminotransferase or total bilirubin level; these were increased to less than 5 times the upper limit of normal in 77% of cases. After adjusting for potential confounders, the presence of gastrointestinal symptoms at any time (odds ratio, 0.93; 95% CI, 0.76-1.15) or liver test abnormalities on admission (odds ratio, 1.31; 95% CI, 0.80-2.12) were not associated independently with mechanical ventilation or death. Among patients hospitalized with COVID-19, gastrointestinal symptoms and liver test abnormalities were common, but the majority were mild and their presence was not associated with a more severe clinical course.
Sections du résumé
BACKGROUND & AIMS
OBJECTIVE
The prevalence and significance of digestive manifestations in coronavirus disease 2019 (COVID-19) remain uncertain. We aimed to assess the prevalence, spectrum, severity, and significance of digestive manifestations in patients hospitalized with COVID-19.
METHODS
METHODS
Consecutive patients hospitalized with COVID-19 were identified across a geographically diverse alliance of medical centers in North America. Data pertaining to baseline characteristics, symptomatology, laboratory assessment, imaging, and endoscopic findings from the time of symptom onset until discharge or death were abstracted manually from electronic health records to characterize the prevalence, spectrum, and severity of digestive manifestations. Regression analyses were performed to evaluate the association between digestive manifestations and severe outcomes related to COVID-19.
RESULTS
RESULTS
A total of 1992 patients across 36 centers met eligibility criteria and were included. Overall, 53% of patients experienced at least 1 gastrointestinal symptom at any time during their illness, most commonly diarrhea (34%), nausea (27%), vomiting (16%), and abdominal pain (11%). In 74% of cases, gastrointestinal symptoms were judged to be mild. In total, 35% of patients developed an abnormal alanine aminotransferase or total bilirubin level; these were increased to less than 5 times the upper limit of normal in 77% of cases. After adjusting for potential confounders, the presence of gastrointestinal symptoms at any time (odds ratio, 0.93; 95% CI, 0.76-1.15) or liver test abnormalities on admission (odds ratio, 1.31; 95% CI, 0.80-2.12) were not associated independently with mechanical ventilation or death.
CONCLUSIONS
CONCLUSIONS
Among patients hospitalized with COVID-19, gastrointestinal symptoms and liver test abnormalities were common, but the majority were mild and their presence was not associated with a more severe clinical course.
Identifiants
pubmed: 33010411
pii: S1542-3565(20)31371-9
doi: 10.1016/j.cgh.2020.09.041
pmc: PMC7527302
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1355-1365.e4Subventions
Organisme : NIGMS NIH HHS
ID : P20 GM130457
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK123704
Pays : United States
Organisme : NIDDK NIH HHS
ID : T35 DK111373
Pays : United States
Informations de copyright
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.
Références
Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430
pubmed: 32145190
Lancet Gastroenterol Hepatol. 2020 May;5(5):434-435
pubmed: 32199469
Cell Rep. 2019 Jul 2;28(1):245-256.e4
pubmed: 31269444
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Am J Gastroenterol. 2020 Jun;115(6):916-923
pubmed: 32301761
Clin Gastroenterol Hepatol. 2020 Jul;18(8):1682-1684
pubmed: 32334083
Gastroenterology. 2020 Aug;159(2):765-767.e2
pubmed: 32333911
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):667-678
pubmed: 32405603
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Gastroenterology. 2020 Jun;158(8):2298-2301.e7
pubmed: 32234303
Ann Am Thorac Soc. 2015 Nov;12 Suppl 2:S150-6
pubmed: 26595731
Gastroenterology. 2020 May;158(6):1831-1833.e3
pubmed: 32142773
Gastroenterology. 2020 Sep;159(3):1137-1140.e2
pubmed: 32389667
Clin Gastroenterol Hepatol. 2020 Jul;18(8):1753-1759.e2
pubmed: 32311512
JAMA Netw Open. 2020 Jun 1;3(6):e2011335
pubmed: 32525549
Am J Respir Crit Care Med. 2012 Oct 1;186(7):640-7
pubmed: 22837381
Gut. 2020 Jun;69(6):1002-1009
pubmed: 32213556
New Microbes New Infect. 2020 Jul;36:100696
pubmed: 32509310
Am J Gastroenterol. 2020 May;115(5):766-773
pubmed: 32287140
Rev Esp Enferm Dig. 2020 May;112(5):383-388
pubmed: 32343593
Gastroenterology. 2020 Jul;159(1):320-334.e27
pubmed: 32407808
Clin Gastroenterol Hepatol. 2020 Jul;18(8):1663-1672
pubmed: 32278065